Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Chief Medical Officer | January 05, 2023 | January 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 05, 2023 · Filed January 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2033-01-05 | Direct | 110,800 |
Reported balance
After 2023-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 110,800 · Balance 110,800 F1: This option, representing a right to purchase a total of 110,800 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, representing a right to purchase a total of 110,800 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 6, 2023 21:59 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,800 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001140361-23-000823 · form4.xml · derivative · entry 1 WOOD LAUREN · CIK 0001769757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,800 Underlying: Common Stock · 110,800 shares Expires 2033-01-05 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 110,800 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 88,600 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001140361-22-002187 · form4.xml · derivative · entry 1 WOOD LAUREN · CIK 0001769757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,600 Underlying: Common Stock · 88,600 shares Expires 2032-01-19 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 88,600 shares of Common Stock, will become exercisable on January 19, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 19, 2026. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:17 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 210,500 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001140361-20-027869 · form4.xml · derivative · entry 1 WOOD LAUREN · CIK 0001769757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,500 Underlying: Common Stock · 210,500 shares Expires 2030-12-08 F1 · derivative.exercise_date: The option was granted on December 8, 2020, subject to stockholder approval of the Issuer's Second Amended and Restated 2014 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, one-quarter of the shares subject to the option shall vest on December 8, 2021, and the remainder shall vest in equal monthly installments thereafter until fully vested on December 8, 2024. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:35 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014767 · form4.xml · derivative · entry 1 WOOD LAUREN · CIK 0001769757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 35,000 shares of Common Stock, will become exercisable on June 23, 2021, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:46 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 62,715 | $0.00 Strike: $6.39 | $0.00 |
DisclosureSEC source: 0001127602-19-021152 · form4.xml · derivative · entry 1 WOOD LAUREN · CIK 0001769757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,715 Underlying: Common Stock · 62,715 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 62,715 shares of Common Stock, will become exercisable on June 6, 2020, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.